

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-7 (Cancelled).

8. (Currently Amended) A composition for transfecting a target cell at a site of vascularization in vivo, which contains as active ingredients:

(1) an effective amount for transfecting a target cell at a site of vascularization of a retrovirus that contains a gene to be transfected;

(2) an effective amount for transfecting a target cell at a site of vascularization of a functional substance having heparin-II-binding domain of fibronectin wherein said functional substance is CH-296; and

(3) an effective amount for transfecting a target cell at a site of vascularization of human umbilical vein endothelial cells as vehicles.

Claims 9-41 (Cancelled).

42. (Previously Presented) The composition according to claim 8, wherein a protein encoded by the gene useful for transfecting a target cell at a site of

vascularization is a therapeutic protein which is expressed upon expression of the gene in the target cell in an amount sufficient for the treatment.

43. (Previously Presented) The composition according to claim 42, wherein the protein is an enzyme or a cytokine.

Claims 44-50 (Cancelled).